All News
The JP Morgan Health Care Conference is held annually in January, and usually kicks off the biggest biopharma business news stories of the year. But in 2022, it’ll do so without at least three big names in the industry.
Good data management means developing a systematic way to integrate and update data enterprise-wide and to share it with team members or partners as needed.
Bristol Myers Squibb is dropping $920 million to acquire the exclusive global rights of Immatics’ experimental cancer drug program, the companies announced Tuesday morning.
Texas’ top law enforcement official is taking aim at two drug companies over what he alleges is the promotion of hormone blockers for children experiencing gender dysphoria.
AnHeart Therapeutics raised $61 million in a Series B financing round. Proceeds from the round will be used for the company’s lead asset, a next-generation ROS1 inhibitor currently in Phase II trials in non-small cell lung cancer.
The FDA said that it is not authorizing molnupiravir’s use during pregnancy as there are hardly any clinical scenarios where the benefits appear to outweigh the risks.
Novartis has grown weary of waiting, dropping out of its deal to fund Mesoblast’s floundering COVID-19 treatment.
The lawsuit was filed by Public Health and Medical Professionals for Transparency, a nonprofit organization recently formed with a mission to obtain the data for the COVID-19 vaccines.
Despite the biggest vaccination drive in the U.S., the pandemic is still not over. The U.S. has reported more than 800,000 COVID-19 deaths, an increase of 500,000 since the vaccination started.
If successfully finalized, the transaction will give CSL access to Vifor’s pipeline of treatments for iron deficiency, kidney and cardio-renal diseases.
The 63rd ASH Annual Meeting and Exposition is wrapping up today, with dozens providing updates on clinical trials and preclinical research. Here’s a highlight of just a few of those stories.
Cidara Therapeutics and Mundipharma today shared positive topline results from their Phase III trial on the use of rezafungin for candidemia and invasive candidiasis.
As of now, six studies related to islatravir are on full clinical hold, while seven are on partial clinical hold. Here are more updates on the development of this drug.
Following up after an interview can be essential to help you gain peace of mind and reinforce your interest. Here’s how to improve follow up after interview.
The deal, which could be worth as much as $12 billion USD, was also confirmed by CSL speaking to Reuters Monday morning.
Making its ASH debut this year was Novartis’ T-Charge CAR-T platform. Novartis presented early data from two first-in-human dose-escalation trials: YTB323 and PHE885.
Takeda will present nine abstracts at the annual ASH meeting, including data for its hemophilia program, as well as announcing a new sickle cell disease program.
BeiGene raised $3.3 billion on Shanghai’s STAR market, making it the first company to trade its shares in Shanghai, Hong Kong, and New York.
BrainStorm Cell Therapeutics is making a strong comeback after the FDA was a little impressed with Phase III results of amyotrophic lateral sclerosis treatment.
At the ASH meeting, Bristol Myers Squibb and Kite Pharma presented promising data from CAR-T programs aimed at relapsed or refractory large B-cell lymphoma.